WP
KRRO icon

WealthSource Partners’s Korro Bio KRRO Stock Holding History

WealthSource Partners’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-465
Closed -$8.6K – 510
2023
Q3 		$8.6K Hold
465
– – ﹤0.01% 488
2023
Q2 		$8.04K Buy
+465
New +$9.02K ﹤0.01% 491

Other funds holding KRRO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WealthSource Partners's KRRO Position: Q4 2023 in Review

WealthSource Partners sold out of Korro Bio (KRRO) in Q4 2023, closing a stake of 465 shares — an estimated $8.6K sold.

WealthSource Partners first reported a position in KRRO in Q2 2023 and held it in 2 quarters. The position peaked at $8.6K in Q3 2023. 40 funds tracked by Wall St. Rank hold KRRO as of Q4 2023.

  • WealthSource Partners reported no remaining Korro Bio position as of Q4 2023 after selling out during the quarter.
  • WealthSource Partners sold 465 Korro Bio shares in Q4 2023, an estimated $8.6K.
  • WealthSource Partners first reported a position in Korro Bio in Q2 2023 and held it in 2 quarters.
  • WealthSource Partners's Korro Bio position peaked at $8.6K in Q3 2023.
  • 40 funds tracked by Wall St. Rank held Korro Bio as of Q4 2023.

Based on WealthSource Partners's 13F filing for Q4 2023, filed 16 Jan 2024.